Optimising VEGFR-TKIs (MKIs) in Differentiated Thyroid Cancer

Episode 1 September 06, 2021 00:21:52
Optimising VEGFR-TKIs (MKIs) in Differentiated Thyroid Cancer
COR2ED Medical Education
Optimising VEGFR-TKIs (MKIs) in Differentiated Thyroid Cancer

Sep 06 2021 | 00:21:52

/

Show Notes

Dr. Jaume Capdevila, a Medical Oncologist at Vall d’Hebron University Hospital in Barcelona, Spain, and Dr. Rachel van Leeuwaarde, an Endocrinologist from the University Medical Center of Utrecht in The Netherlands discuss the use of multi-kinase inhibitors (MKIs), in particular VEGFR-TKIs in patients with radioactive iodine refractory differentiated thyroid cancer (DTC).

In this podcast, the two experts discuss key trials (SELECT, DECISION and COSMIC-311) and efficacy parameters of the current VEGFR-TKIs (lenvatinib, sorafenib and cabozantinib), how to manage toxicity whilst trying to optimise treatment outcomes and preserving always patients’ quality of life. They also discuss treatment strategies, when to start systemic treatment, which drug should be used first and how to sequence therapies. To close the podcast they take a look at ongoing clinical trials with other treatments in development for DTC.

Other Episodes

Episode 1

November 16, 2022 00:21:45
Episode Cover

Treating von Willebrand Disease: Does the Type Matter?

COR2ED Medical Education: Haematologists Prof. Ana Boban and Dr Jonathan Roberts discuss how the type of von Willebrand disease (VWD) impacts the treatment. In...

Listen

Episode 1

June 28, 2022 00:18:42
Episode Cover

PBC Highlights from ILC 2022: Ep. 1

COR2ED Medical Education: In this podcast, Prof. Gideon Hirschfield, Professor of Medicine, Division of Gastroenterology, University of Toronto, Canada and Prof. Ana Lleo, Professor...

Listen

Episode 14

June 20, 2023 00:23:12
Episode Cover

Breast Cancer : Oral SERDs in ER+ breast cancer. Episode 1 - efficacy and safety and treatment landscape

COR2ED Medical Education: In this podcast, the experts give an overview of  the EMERALD trial  and present elacestrant as the first, and currently only,...

Listen